Cargando…

New Era for Next-Generation Sequencing in Japan

Recent progress in understanding the molecular basis of cancer—including the discovery of cancer-associated genes such as oncogenes and tumor suppressor genes—has suggested that cancer can become a treatable disease. The identification of driver oncogenes such as EGFR, ALK, ROS1, BRAF and HER2 has a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Masayuki, Sakai, Kazuko, Takahama, Takayuki, Fukuoka, Kazuya, Nakagawa, Kazuhiko, Nishio, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627271/ https://www.ncbi.nlm.nih.gov/pubmed/31142054 http://dx.doi.org/10.3390/cancers11060742

Ejemplares similares

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter
por: SAKAI, KAZUKO, et al.
Publicado: (2015)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
por: Sakai, Kazuko, et al.
Publicado: (2019)

Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
por: Takahama, Takayuki, et al.
Publicado: (2016)

Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan
por: Takahashi, Toshiaki, et al.
Publicado: (2023)

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
por: Sakai, Kazuko, et al.
Publicado: (2020)

A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer
por: Takahama, Takayuki, et al.
Publicado: (2015)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
por: Kato, Ryoji, et al.
Publicado: (2020)

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021)

Disease vectors in the era of next generation sequencing
por: Rinker, David C., et al.
Publicado: (2016)

Unrevealed mosaicism in the next-generation sequencing era
por: Gajecka, Marzena
Publicado: (2015)

Metabolic Myopathies in the Era of Next-Generation Sequencing
por: Urtizberea, Jon Andoni, et al.
Publicado: (2023)

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis
por: Sakai, Kazuko, et al.
Publicado: (2021)

Trends in Next-Generation Sequencing and a New Era for Whole Genome Sequencing
por: Park, Sang Tae, et al.
Publicado: (2016)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)
por: Sunami, Kuniko, et al.
Publicado: (2018)

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing
por: Iwama, Eiji, et al.
Publicado: (2018)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

MS3-1 IMPLEMENTATION OF GENE PANEL TESTING USING NEXT-GENERATION SEQUENCING
por: Sakai, Kazuko
Publicado: (2019)

Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy
por: Yoshii, Yumi, et al.
Publicado: (2021)

Principles of Genetic Counseling in the Era of Next-Generation Sequencing
por: Yang, Mina, et al.
Publicado: (2018)

Perspectives of Integrative Cancer Genomics in Next Generation Sequencing Era
por: Kwon, So Mee, et al.
Publicado: (2012)

Congenital Cataract and Its Genetics: The Era of Next-Generation Sequencing
por: Taylan Şekeroğlu, Hande, et al.
Publicado: (2021)

Analytical Tools and Databases for Metagenomics in the Next-Generation Sequencing Era
por: Kim, Mincheol, et al.
Publicado: (2013)

Genetics of Primary Ovarian Insufficiency in the Next-Generation Sequencing Era
por: França, Monica Malheiros, et al.
Publicado: (2019)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Clinical and immune profiling for cancer of unknown primary site
por: Haratani, Koji, et al.
Publicado: (2019)

Novel genes and variants associated with congenital pituitary hormone deficiency in the era of next-generation sequencing
por: Bando, Hironori, et al.
Publicado: (2022)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
por: Takeda, Masayuki, et al.
Publicado: (2019)

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
por: Nishio, Kazuto, et al.
Publicado: (2023)

Tackling Skeletal Muscle Cells Epigenome in the Next-Generation Sequencing Era
por: Fittipaldi, Raffaella, et al.
Publicado: (2012)

Diagnosis, investigation and management of hereditary spastic paraplegias in the era of next-generation sequencing
por: Hensiek, Anke, et al.
Publicado: (2014)

Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing
por: Stanislaw, Christine, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_98cg32u8gfkehu60mi44vcmle1